natgillin/translations-raw huggingface dataset:
The primary forum for this coordination is the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), a network that includes nearly 30 research funders as well as the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI) as observers. 
Glavni forum za to usklajevanje je globalno raziskovalno sodelovanje za pripravljenost na nalezljive bolezni (GloPID-R), mreža, ki vključuje skoraj 30 financerjev raziskav in SZO ter koalicijo za inovacije na področju pripravljenosti na epidemije (CEPI) v vlogi opazovalcev.
Hesitancy is a growing concern in Europe and worldwide, which risks undermining the public health value of vaccination. 
Nezaupanje povzroča vse večjo zaskrbljenost v Evropi in svetu, saj ogroža vrednost cepljenja za javno zdravje.
Develop EU guidance for establishing comprehensive electronic immunisation information systems for effective monitoring of immunisation programmes; 
priprava smernic EU za vzpostavitev celovitih elektronskih informacijskih sistemov za imunizacijo za učinkovito spremljanje programov cepljenja;
Establish partnerships and research infrastructures, including for clinical trials, facilitating early dialogue with developers, public health organisations and regulators to support the authorisation of innovative vaccines, including for emerging health threats; 
vzpostavitev partnerstev in raziskovalne infrastrukture, med drugim za klinično preskušanje, da se omogoči zgodnji dialog z razvijalci, javnozdravstvenimi organizacijami in regulativnimi organi v podporo izdaji dovoljenj za inovativna cepiva, vključno s cepivi proti nastajajočim nevarnostim za zdravje;
Vaccine hesitancy is highly specific to the context, country, and type of vaccine, and the public perception of a given vaccine can change rapidly. 
Nezaupanje v cepljenje je v veliki meri odvisno od razmer, države in vrste cepiva, javno mnenje o določenem cepivu pa se lahko hitro spremeni.
Furthermore, ageing, mobility of people, and the shift in the burden of traditional vaccine-preventable diseases from childhood to later years of life call for a careful assessment of the cost-effectiveness of a life-course approach to vaccination. 
Poleg tega staranje, mobilnost ljudi ter prenos bremena tradicionalnih bolezni, ki jih je mogoče preprečiti s cepljenjem, iz otroštva v poznejša leta zahtevajo natančno oceno stroškovne učinkovitosti vseživljenjskega pristopa k cepljenju.
Develop operational opportunities at EU level, such as the European Vaccination Information Sharing system, to increase coordination on relevant vaccination activities 
razvoj operativnih priložnosti na ravni EU, kot je evropski sistem za izmenjavo informacij o cepljenju, za večjo usklajenost zadevnih dejavnosti cepljenja;
Recent fatal cases of diphtheria in the EU have also reminded that individuals who are not immunised against diseases rarely seen remain at risk. 
Nedavni smrtni primeri davice v EU so nas opomnili, da so posamezniki, ki niso imunizirani proti redkim boleznim, še vedno izpostavljeni tveganju.
In recent years, the G7 and G20 have addressed global health including health security. 
V zadnjih letih je bilo svetovno zdravje, vključno z zdravstveno varnostjo, obravnavano v skupinah G7 in G20.
Vaccination is an area which could receive further political impetus if addressed by these groups. 
Če bosta ti skupini cepljenje obravnavali tudi v prihodnje, bi bilo to področje lahko deležno nadaljnje politične spodbude.
Vaccine hesitancy in Europe can also be driven by issues related to the affordability, geographical accessibility, or availability of information on immunisation. 
Razlog za nezaupanje v cepljenje v Evropi so lahko tudi težave, povezane s cenovno in geografsko dostopnostjo ali razpoložljivostjo informacij o imunizaciji.
There is a strong need for better global preparedness against communicable diseases, and the impact of strong immunisation programmes in the EU and worldwide is key to the success of the International Health Regulations. 
Nujno potrebna je boljša pripravljenost na nalezljive bolezni v svetovnem merilu, vpliv dobrih programov imunizacije v EU in po svetu pa je bistven za uspešno izvajanje Mednarodnega zdravstvenega pravilnika.
Improving access to high-quality objective and transparent information on vaccines and vaccination, including on effectiveness and safety aspects, is crucial. 
Ključnega pomena je izboljšanje dostopa do visokokakovostnih objektivnih in preglednih informacij o cepivih in cepljenju, vključno z njegovo učinkovitostjo in varnostjo.
Any encounter with the healthcare system should be used as an opportunity for catch-up vaccinations to close immunity gaps. 
Vse stike z zdravstvenim sistemom bi bilo treba izkoristiti kot priložnost za naknadno cepljenje za odpravo nezadostne imunizacije.
As a result, vaccination schedules vary between Member States on aspects such as timing, doses administered, type of healthcare workers involved in the delivery and vaccine purchasing practices. 
Posledično se v državah članicah razlikujejo določeni vidiki cepljenja, kot so časovni razporedi, odmerki, tip zdravstvenih delavcev, ki izvajajo cepljenje, in prakse javnega naročanja.
PILLAR I - Tackling vaccine hesitancy and improving vaccination coverage 
STEBER I - Odprava nezaupanja v cepljenje in izboljšanje precepljenosti
Improve access to objective and transparent information on vaccines and their safety, following the assessment of information needs on the part of both public and healthcare workers; 
izboljšanje dostopa do objektivnih in preglednih informacij o cepivih ter njihovi varnosti, ko se ocenijo informacijske potrebe javnosti in tudi zdravstvenih delavcev;
They may not understand the rationale for different policies across countries, raising doubts on the scientific base for the decision-making of vaccination policies. 
Morda bodo zaradi različnih nacionalnih politik začeli dvomiti o znanstveni osnovi za sprejemanje odločitev v zvezi s politikami cepljenja.
EU action should allow the standardisation of tools and methodologies to assess and report on coverage data across all ages, beyond the traditional paediatric age group, leveraging, in particular, the potential of electronic immunisation information systems. 
Ukrepi EU bi morali omogočiti standardizacijo orodij in metodologij za ovrednotenje in sporočanje podatkov o precepljenosti za vsa starostna obdobja, ne le tradicionalne pediatrične starostne skupine, pri čemer bi zlasti izboljšali potencial elektronskih informacijskih sistemov za imunizacijo.
There are also technical bottlenecks which span the entire product development pipeline, and novel adjuvants are needed for vaccines for which conventional formulations have failed. 
Obstajajo tudi tehnična ozka grla, ki zajemajo celotno linijo proizvodov, za cepiva, pri katerih konvencionalne formulacije niso bile uspešne, pa so potrebni novi adjuvanti.
Access to vaccination must be widened and made easier to the recipient, particularly for vulnerable and underserved communities. 
Povečati in olajšati je treba dostop do cepljenja, zlasti v ranljivih in manj pokritih skupnostih.
[18: Global Research Collaboration for Infectious Disease Preparedness https://www.glopid-r.org/] 
[18: Globalno raziskovalno sodelovanje za pripravljenost na nalezljive bolezni, https://www.glopid-r.org/.]
As hesitancy differs across countries, populations and vaccines, having reliable stratified coverage data can help detecting sub-groups with lower uptake, assess the root-cause, and thus tailor the necessary intervention. 
Ker se nezaupanje razlikuje po državah, prebivalstvu in glede na cepivo, lahko zanesljivi stratificirani podatki o precepljenosti pomagajo prepoznati podskupine z manjšo precepljenostjo, ovrednotiti temeljni vzrok za nezaupanje ter posledično prilagoditi potrebno posredovanje.
Effort is needed at EU and Member State level to develop operational guidelines and remove infrastructural, legal and standardisation barriers to facilitate interoperability and electronic data sharing in the area of vaccination, and harness the deployment of immunisation information systems to inform operational and strategic decisions. 
Na evropski in nacionalni ravni si je treba prizadevati za pripravo operativnih smernic in odpravo infrastrukturnih, pravnih in standardizacijskih ovir, da se omogočita interoperabilnost in elektronska izmenjava podatkov na področju cepljenja ter izkoristi uvedba informacijskih sistemov za imunizacijo za poročanje o operativnih in strateških odločitvah.
There is value in better EU-coordinated efforts and pooling of joint EU technical expertise to assess the evidence in the pre- and post-licensing phase of a vaccine. 
Smiselno je boljše usklajevanje prizadevanj na ravni EU ter združevanje skupnega evropskega tehničnega znanja za vrednotenje dokazov v obdobju pred izdajo dovoljenja za cepivo in po njem.
EU coordination and contribution to global health 
STEBER III - Usklajevanje na evropski ravni in prispevanje k zdravju na svetovni ravni
Create a sustainable and multi-stakeholder platform for EU post-authorisation studies monitoring the safety, effectiveness, and impact of vaccination; 
oblikovanje trajnostne platforme več zainteresiranih strani za evropske študije o spremljanju varnosti, učinkovitosti in vpliva cepljenja po izdaji dovoljenja;
Yet in spite of the overall benefits of vaccination, a number of key challenges still remain to ensure sustainable, equitable and effective vaccination programmes in all Member States, and to secure that the added benefits of vaccination are not lost. 
Splošnim koristim cepljenja navkljub pa je za zagotovitev trajnostnih, enakih in učinkovitih programov cepljenja v vseh državah članicah ter za zagotovitev, da se dodatne koristi cepljenja ne izgubijo, treba premagati še več ključnih izzivov.
Mitigate risks of shortages by developing a virtual EU data warehouse on vaccine needs to facilitate voluntary exchange of information on available supplies and shortages of essential vaccines; 
zmanjšanje tveganj pomanjkanja cepiv z razvojem virtualnega evropskega podatkovnega skladišča za beleženje potreb po cepivih, da se olajša prostovoljna izmenjava informacij o razpoložljivih zalogah in pomanjkanju osnovnih cepiv;
The most pressing challenges include overcoming vaccine hesitancy (the delay in acceptance or refusal of vaccines despite availability of vaccination services), halting the spread of vaccine preventable communicable diseases, sustaining high vaccine coverage, and guaranteeing equal access to vaccination across all ages and populations. 
Najbolj pereči izzivi vključujejo odpravo nezaupanja v cepljenje (poznejša privolitev v cepljenje ali zavrnitev cepljenja kljub razpoložljivosti storitve), zaustavitev širjenja nalezljivih bolezni, ki jih je mogoče preprečiti s cepljenjem, ohranitev visoke stopnje precepljenosti in zagotavljanje enakega dostopa do cepljenja prebivalcem vseh starosti.
The financial sustainability of vaccination programmes is also key, to ensure stronger support to monitor the impact and effectiveness of vaccines, to mitigate the risk of shortages, and to tackle vaccine hesitancy and its impact on immunisation programmes. 
Finančna vzdržnost programov cepljenja je prav tako ključna za zagotavljanje močnejše podpore spremljanju vpliva in učinkovitosti cepiv, zmanjševanje tveganj pomanjkanja cepiv in odpravljanje nezaupanja v cepljenje ter njegovega vpliva na programe imunizacije.
Adult vaccination, questions around immune-senescence (loss of immunity over time), and new vaccines licensed for adults and older people are becoming central topics of interest, with the potential for public health and economic gains. 
Cepljenje odraslih, vprašanja glede imunskega staranja (upad imunosti skozi čas) ter nova cepiva za odrasle in starejše postajajo osrednje interesne teme, ki so smiselne z javnozdravstvenega in tudi z gospodarskega vidika.
Bolster the effectiveness and efficiency of EU and national vaccine research and development funding and develop a roadmap on priority areas of needs. 
povečanje uspešnosti in učinkovitosti financiranja raziskav in razvoja na področju cepiv na nacionalni in evropski ravni ter priprava načrta o prednostnih področjih glede na opredeljene potrebe.
Establish guidelines for a core EU vaccination schedule to facilitate compatibility of national schedules and promote equity in citizens' health protection, that can be used as reference to optimise national schedules, as well as meet the needs of citizens moving across borders; 
vzpostavitev smernic za temeljni razpored cepljenja v EU, da se omogoči združljivost nacionalnih razporedov, spodbuja enakost zdravstvenega varstva državljanov, pri čemer bi se navedeni razpored lahko uporabil kot referenca za optimizacijo nacionalnih razporedov, in izpolnijo potrebe državljanov pri selitvi v drugo državo;
The decrease in certain diseases incidence together with action undertaken by anti-vaccination activists, have led to a shift of focus from the dangers, and even risk of death, posed by unseen diseases towards fear of unproven side events. 
Upad incidence določenih bolezni je skupaj z ukrepi skupin nasprotnikov cepljenja privedel do preusmeritve pozornosti z nevarnosti in celo tveganja umrljivosti, ki ga predstavljajo bolezni, ki se dandanes redkeje pojavljajo, na strah pred nedokazanimi stranskimi učinki.
Foster behavioural research to better understand context-specific determinants of hesitancy from the end-user perspective, and design tailored intervention strategies; 
spodbujanje vedenjskih raziskav za boljše razumevanje razmeram prilagojenih odločilnih dejavnikov nezaupanja z vidika končnega uporabnika in zasnova prilagojenih strategij posredovanja;
This is despite the fact that vaccines in the EU undergo rigorous testing both pre- and post- licensure, in line with Directive 2001/83/EC and Regulation (EU) No.726/2004. 
Tako je kljub dejstvu, da cepiva v EU v skladu z Direktivo 2001/83/ES in Uredbo (ES) št. 726/2004 prestanejo strogo preskušanje pred izdajo dovoljenja in tudi po njej.
Challenges linked to vaccine shortages cut across both demand and supply side issues, and include production issues, limited supplier base and production capacities, global increase in demand, as well as insufficient forecasting services, inflexible procurement design and limited stockpiling options. 
Izzivi, povezani s pomanjkanjem cepiv, zadevajo povpraševanje in tudi ponudbo ter vključujejo težave s proizvodnjo, omejene dobavne in proizvodne zmogljivosti, svetovno povečanje povpraševanja, pomanjkljive napovedi potreb, okorelo zasnovo javnega naročanja ter omejene možnosti skladiščenja zalog.
Produce, in the context of the State of Health in the EU process, a State of Confidence in Vaccines in the EU report to generate data for action at national and EU level; 
priprava poročila o zaupanju v cepiva v EU v okviru cikla o zdravstvenem stanju v EU, ki bo vsebovalo podatke za ukrepanje na nacionalni in evropski ravni;
Concerted actions will enhance the sustainability of national vaccination programmes and strengthen national capacities to tackle growing vaccine hesitancy, global vaccine shortages, disinvestment of vaccine manufacturers, and lack of coordination in vaccine research and development. 
Usklajeni ukrepi bodo izboljšali trajnost nacionalnih programov cepljenja in okrepili nacionalne zmogljivosti za odpravo rastočega nezaupanja v cepljenje, svetovnega pomanjkanja cepiv, dezinvestiranja proizvajalcev cepiv in neusklajevanja pri raziskavah in razvoju na področju cepiv.
In recent years, significant outbreaks of vaccine-preventable diseases and a number of events with cross-border relevance have brought to the fore the continued gaps the EU is facing in vaccination coverage. 
V zadnjih letih so večji izbruhi bolezni, ki jih je mogoče preprečiti s cepljenjem, in številni dogodki čezmejnega pomena v ospredje postavili nezadostno precepljenost, s katero se še vedno sooča EU.
Through GloPID-R, research funders are developing a strategic research agenda for infectious diseases with pandemic potential, and the network responds to major disease outbreaks by launching clinical studies, including for vaccine development. 
Prek te mreže financerji raziskav razvijajo strateški raziskovalni program za nalezljive bolezni, ki bi lahko povzročile pandemijo, mreža pa se z uvedbo kliničnih preskušanj, tudi na področju razvoja cepiv, odziva na večje izbruhe bolezni.
[13: Commission SWD on Investing in Health https://ec.europa.eu/health/sites/health/files/policies/docs/swd_investing_in_health.pdf] 
[13: Delovni dokument služb Komisije, Investing in Health (naložbe v zdravje), https://ec.europa.eu/health/sites/health/files/policies/docs/swd_investing_in_health.pdf.]
Develop a common EU citizens vaccination card retrievable through electronic information systems and recognised for use across borders, in view of standardising the reporting on immunisation history; 
razvoj skupne knjižice o cepljenju za državljane EU, ki bo dostopna prek elektronskih informacijskih sistemov in odobrena za čezmejno uporabo, da se poenoti poročanje o predhodni imunizaciji;
In Europe, safety-related concerns are a key determinant of hesitancy for both members of the public and healthcare professionals. 
V Evropi so glavni odločilni dejavnik nezaupanja v cepljenje pri javnosti in tudi pri zdravstvenih strokovnjakih pomisleki, povezani z varnostjo.
SDG 3 on ensuring healthy lives and promoting well-being for all at all ages, underlines the importance of vaccines in protecting people against disease. 
Imunizacija bo imela pomembno vlogo tudi pri doseganju ciljev trajnostnega razvoja Agende 2030. 3. cilj trajnostnega razvoja o skrbi za zdravo življenje in spodbujanju splošnega dobrega počutja v vseh življenjskih obdobjih poudarja pomembnost cepiv pri zaščiti ljudi pred boleznimi.
[1: WHO, Immunization Coverage, Fact Sheet 2018, http://www.who.int/mediacentre/factsheets/fs378/en/][2: Rappuoli R (2014), DG Research New Horizon for Vaccine Conference, https://ec.europa.eu/research/health/pdf/event17/s2-2-rino-rappuoli_en.pdf] 
][2: Rappuoli R., 2014, GD za raziskave in inovacije, New Horizon for Vaccine Conference (konferenca o novih obzorjih glede cepljenja), https://ec.europa.eu/research/health/pdf/event17/s2-2-rino-rappuoli_en.pdf.]
This is why the Commission will also present a Council Recommendation on strengthened cooperation against vaccine preventable diseases so that Member States and the Commission work hand in hand. 
Razsežnost prihodnjih izzivov zahteva tesno sodelovanje vseh zainteresiranih strani, zato bo Komisija predstavila tudi Priporočilo Sveta o okrepljenem sodelovanju v boju proti boleznim, ki jih je mogoče preprečiti s cepljenjem, da bodo države članice in Komisija tesno sodelovale.
[11: Directive 2000/54/EC on the protection of workers from risks related to exposure to biological agents at work, http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32000L0054&from=EN][12: Directive 2010/32/EU of 10 May 2010 implementing the Framework Agreement on prevention from sharp injuries in the hospital and healthcare sector concluded by HOSPEEM and EPSU, http;//eur-lex.europa.eu/legal-content&&EN/TXT/HTML/?uri=CELEX:32010L0032&from=EN] 
][12: Direktiva 2010/32/EU z dne 10. maja 2010 o izvajanju okvirnega sporazuma o preprečevanju poškodb z ostrimi pripomočki v bolnišnicah in zdravstvenem sektorju, ki sta ga sklenila HOSPEEM in EPSU, http://eur-lex.europa.eu/legal-content/SL/TXT/HTML/?uri=CELEX:32010L0032&qid=1526462779154&from=SL.]
Differences exist as to the formats and languages used, but also with regards to the type of information recorded. 
Razlikujejo se tudi sistemi za dokumentiranje posameznikove predhodne imunizacije, in sicer obstaja vse od papirnatih do naprednih elektronskih informacijskih sistemov, razlikujejo pa se tudi uporabljeni formati in jeziki ter celo vrsta zabeleženih informacij.
[8: Council Recommendation on seasonal influenza vaccination, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF][9: Commission SWD 2014 on State of play on implementation of the Council Recommendation on seasonal influenza vaccination, https://ec.europa.eu/health//sites/health/files/vaccination/docs/seasonflu_staffwd2014_en.pdf][10: ECDC Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013-14 and 2014-15 influenza seasons. 
][10: ECDC, Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013-14 and 2014-15 influenza seasons (pregled priporočil o cepljenju in stopenj precepljenosti v državah članicah EU v sezonah gripe 2013-14 in 2014-15), http://ecdc.europa.eu/en/publications/Publications/Seasonal-influenza-vaccination-antiviral-use-europe.pdf.]
The State of Vaccine Confidence 2016: Global Insights Through 67-Country Survey. 
[14: Larson H, De Figueiredo A, Xiahong Z, et al. The State of Vaccine Confidence 2016: Global Insights Through 67-Country Survey (stanje na področju zaupanja v cepljenje v letu 2016: informacije na svetovni ravni na podlagi ankete, opravljene v 67 državah).
][15: ECDC Vaccine hesitancy among healthcare workers and their patients in Europe, 2015. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/vaccine-hesitancy-among-healthcare-workers.pdf][16: Directive 2001/83/EC on the Community code relating to medicinal products for human use, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:311:0067:0128:en:PDF][17: Regulation 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf] 
][17: Uredba (ES) št. 726/2004 o postopkih Skupnosti za pridobitev dovoljenja za promet in nadzor zdravil za humano in veterinarsko uporabo ter o ustanovitvi Evropske agencije za zdravila, https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_sl.pdf.]
Post-authorisation passive and active monitoring and specifically designed studies are also needed to provide further real-life robust evidence on the safety, effectiveness, and impact of vaccines after use, and overcome current fragmented efforts at EU level. 
Za pridobivanje nadaljnjih trdnih dokazov v realnih situacijah o varnosti, učinkovitosti in vplivu cepiv po uporabi ter poenotenje sedanjih razdrobljenih prizadevanj na ravni EU je treba zagotoviti tudi pasivno in aktivno spremljanje po izdaji dovoljenja ter namensko zasnovane študije.
A fatal case of diphtheria in Belgium, 24 March 2016, https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/RRA-Diphtheria-Belgium.pdf][7: 2016 WHO/UNICEF Estimates of National Immunization Coverage http://www.who.int/immunization/monitoring_surveillance/who-immuniz.pdf?ua=1] 
[6: ECDC, A fatal case of diphtheria in Belgium (smrtni primer davice v Belgiji), 24. marec 2016, https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/RRA-Diphtheria-Belgium.pdf.
Monthly measles and rubella monitoring report, January 2018, https://ecdc.europa.eu/sites/portal/files/documents/Monthly%20measles%20and%20rubella%20monitoring%20report%20-%20JAN%202018.pdf][4: http://www.euro.who.int/en/media-centre/sections/press-releases/2018/europe-observes-a-4-fold-increase-in-measles-cases-in-2017-compared-to-previous-year][5: These estimates refer to children in the vaccination target group below 2 years of age, ECDC, unpublished.] 
[3: ECDC, Monthly measles and rubella monitoring report (mesečno poročilo o spremljanju ošpic in rdečk), januar 2018, https://ecdc.europa.eu/sites/portal/files/documents/Monthly%20measles%20and%20rubella%20monitoring%20report%20-%20JAN%202018.pdf.
[1: European Centre for Disease Prevention and Control. 
[1: Evropski center za preprečevanje in obvladovanje bolezni.
Rapid literature review on motivating hesitant population groups in Europe to vaccinate. 
Rapid literature review on motivating hesitant population groups in Europe to vaccinate (Kratek pregled literature o spodbujanju neodločenih skupin prebivalstva v Evropi k cepljenju).
Determinants of hesitancy 
Razlogi za nezaupanje
Vaccination coverage in the EU 
Precepljenost v EU